Crystallography for protein kinase drug design: PKA and SRC case studies

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1754, Issue 1-2, 2005, Pages 38-49

  Breitenlechner, Christine B ^a   Bossemeyer, Dirk ^b   Engh, Richard A ^c  

^a PROTEROS BIOSTRUCTURES GMBH   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Crystal structure; Drug design; Flexibility; PKA; Protein kinase inhibitor; SRC

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; FASUDIL; PROTEIN KINASE; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; RHO KINASE INHIBITOR; UNCLASSIFIED DRUG;

BRAIN VASOSPASM; CONFERENCE PAPER; CONFORMATION; CRYSTAL STRUCTURE; CRYSTALLIZATION; CRYSTALLOGRAPHY; DRUG DESIGN; GENETIC HETEROGENEITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN STRUCTURE; SEQUENCE HOMOLOGY; STRUCTURAL GENOMICS; STRUCTURAL PROTEOMICS;

ANIMALS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SRC-FAMILY KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 29144463345     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2005.09.014     Document Type: Conference Paper

References (68)

1. W.G.J. Hol Structural genomics for science and society Nat. Struct. Biol. 2000 964 966
2. J. Westbrook, Z.K. Feng, L. Chen, H.W. Yang, and H.M. Berman The protein data bank and structural genomics Nucleic Acids Res. 31 2003 489 491
3. H. Gohlke, and G. Klebe Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors Angew. Chem., Int. Ed. 41 2002 2644 2676
4. D.H. Williams, E. Stephens, D.P. O'Brien, and M. Zhou Understanding noncovalent interactions: ligand binding energy and catalytic efficiency from ligand-induced reductions in motion within receptors and enzymes Angew. Chem., Int. Ed. 43 2004 6596 6616
5. B.A. Posner High-throughput screening-driven lead discovery: meeting the challenges of finding new therapeutics Curr. Opin. Drug Discov. 8 2005 487 494
6. D. Schuster, C. Laggner, and T. Langer Why drugs fail-A study on side effects in new chemical entities Curr. Pharm. Des. 11 2005 3545 3559
7. K.H. Bleicher, H.-J. Böhm, K. Müller, and A.I. Alanine Hit and lead generation: beyond high-throughput screening Nat. Rev., Drug Discov. 2 2003 369 378
8. T. Lundqvist The devil is still in the details-Driving early drug discovery forward with biophysical experimental methods Curr. Opin. Drug Discov. Dev. 8 2005 513 519
9. K.R. Acharya, and M.D. Lloyd The advantages and limitations of protein crystal structures Trends Pharm. Sci. 26 2005 10 14
10. K.A. Kantardjieff, and B. Rupp Matthews coefficient probabilities: improved estimates for unit cell contents of proteins, DNA, and protein-nucleic acid complex crystals Protein Sci. 12 2003 1865 1871
11. M.A. DePristo, P.I.W. de Bakker, and T.L. Blundell Heterogeneity and inaccuracy in protein structures solved by X-ray crystallography Structure 12 2004 831 838
12. Z.S. Derewenda Rational protein crystallization by mutational surface engineering Structure 12 2004 529 535
13. J. Yang, P. Cron, V.M. Good, V. Thompson, B.A. Hemmings, and D. Barford Crystal structure of an activated Akt/Protein Kinase B ternary complex with GSK3-peptide and AMP-PNP Nat. Struct. Biol. 9 2002 940 944
14. G. Manning, D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam The protein kinase complement of the human genome Science 298 2002 1912 1934
15. M. Cherry, and D.H. Williams Recent kinase and kinase inhibitor X-ray structures: mechanisms of inhibition and selectivity insights Curr. Med. Chem. 11 2004 663 673
16. H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H. Weissig, I.N. Shindyalov, and P.E. Bourne The protein data bank Nucleic Acids Res. 28 2000 235 242
17. B. Nolen, S.S. Taylor, and G. Ghosh Regulation of protein kinases: controlling activity through activation segment conformation Mol. Cell 15 2004 661 675
18. R.A. Engh, and D. Bossemeyer Structural aspects of protein kinase control-role of conformational flexibility Pharmacol. Ther. 93 2002 99 111
19. C. Kim, N.-H. Xuong, and S.S. Taylor Crystal structure of a complex between the catalytic and regulatory subunits (RIa) of PKA Science 307 2005 690 696
20. Z.-B. Xu, D. Chaudhary, S. Olland, S. Wolfrom, R. Czerwinski, K. Malakian, L. Lin, M.L. Stahl, D. Joseph-McCarthy, C. Benander, L. Fitz, R. Greco, W.S. Somers, and L. Mosyak Catalytic domain crystal structure of protein kinase C-theta (PKC-theta) J. Biol. Chem. 279 2004 50401 50409
21. A. Messerschmidt, S. Macieira, M. Velarde, M. Bädeker, C. Benda, A. Jestel, H. Brandstetter, T. Neuefeind, and M. Blaesse Crystal structure of the catalytic domain of human atypical protein kinase C-iota reveals interaction mode of phosphorylation site in turn motif J. Mol. Biol. 352 2005 918 931
22. N. Ono-Saito, I. Niki, H. Hidaka, and H. H-series protein kinase inhibitors Potential clinical applications Pharmacol. Ther. 82 1999 123 131
23. C. Breitenlechner, M. Gaßel, R. Engh, and D. Bossemeyer Structural insights into AGC kinase inhibition Oncol. Res. 14 2004 267 278
24. S.S. Taylor, J. Yang, J. Wu, N.M. Haste, E. Radzio-Andzelm, and G. Anand PKA: a portrait of protein kinase dynamics Biochim. Biophys. Acta 1697 2004 259 269
25. T. Hunter, and B.M. Sefton Transforming gene product of Rous sarcoma virus phosphorylates tyrosine Proc. Natl. Acad. Sci. U. S. A. 77 1980 1311 1315
26. S.V. Russello, and S.K. Shore SRC in human carcinogenesis Front. Biosci. 8 2003 S1068 S1073
27. R. Roskoski Src protein-tyrosine kinase structure and regulation Biochem. Biophys. Res. Commun. 324 2004 1155 1164
28. T.J. Boggon, and M.J. Eck Structure and regulation of Src family kinases Oncogene 23 2004 7918 7927
29. C.A. Lowell Src-family kinases: rheostats of immune cell signalling Mol. Immun. 41 2004 631 643
30. H. Yamaguchi, and W.A. Hendrickson Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation Nature 384 1996 484 489
31. S.W. Cowan-Jacob, G. Fendrich, P.W. Manley, W. Jahnke, D. Fabbro, J. Liebetanz, and T. Meyer The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation Structure 13 2005 861 871
32. C.B. Breitenlechner, N.A. Kairies, K. Honold, S. Scheiblich, H. Koll, E. Greiter, S. Koch, W. Schäfer, R. Huber, and R.A. Engh Crystal structures of active Src kinase domain complexes J. Mol. Biol. 353 2005 222 231
33. I.D. Kuntz, K. Chen, K.A. Sharp, and P.A. Kollman The maximal affinity of ligands Proc. Natl. Acad. Sci. U. S. A. 96 1999 9997 10002
34. R. Talhout, A. Villa, A.E. Mark, and J.B. Engberts Understanding binding affinity: a combined isothermal titration calorimetry/molecular dynamics study of the binding of a series of hydrophobically modified benzamidinium chloride inhibitors to trypsin J. Am. Chem. Soc. 125 2003 10570 10579
35. M.E.M. Noble, J.A. Endicott, and L.N. Johnson Protein kinase inhibitors: insights into drug design from structure Science 303 2004 1800 1805
36. H. Daub, K. Godl, D. Brehmer, B. Klebl, and G. Muller Evaluation of kinase inhibitor selectivity by chemical proteomics Assay Drug Dev. Tech. 2 2004 215 224
37. M. Vieth, R.E. Higgs, D.H. Robertson, M. Shapiro, E.A. Gragg, and H. Hemmerle Kinomics-Structural biology and chemogenomics of kinase inhibitors and targets Biochim. Biophys. Acta, Protein Proteom. 1697 2004 243 257
38. Z.A. Knight, and K.M. Shokat Features of selective kinase inhibitors Chem. Biol. 12 2005 621 637
39. T. Schindler, W. Bornmann, P. Pellicena, W.T. Miller, B. Clarkson, and J. Kuriyan Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase Science 289 2000 1938 1942
40. C. Pargellis, L. Tong, L. Churchill, P.F. Cirillo, T. Gilmore, A.G. Graham, P.M. Grob, E.R. Hickey, N. Moss, S. Pav, and J. Regan Inhibition of p38 map kinase by utilizing a novel allosteric binding site Nat. Struct. Biol. 9 2002 268 272
41. S.F. Barnett, D. Defeo-Jones, S. Fu, P.J. Hancock, K.M. Haskell, R.E. Jones, J.A. Kahana, A.M. Kral, K. Leander, L.L. Lee, J. Malinowski, E.M. McAvoy, D.D. Nahas, R.G. Robinson, and H.E. Huber Identification and characterization of pleckstrin-homology-domain dependent and isoenzyme-specific Akt inhibitors Biochem. J. 385 2005 399 408
42. C.E. Fitzgerald, S.B. Patel, J.W. Becker, P.M. Cameron, D. Zaller, V.B. Pikounis, S.J. O'Keefe, and G. Scapin Structural basis for p38alpha MAP kinase quinazoline and pyridol-pyrimidine inhibitor specificity Nat. Struct. Biol. 10 2003 764 769
43. L. Tong, S. Pav, D.M. White, S. Rogers, K.M. Crane, C.L. Cywin, M.L. Brown, and C.A. Pargellis A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket Nat. Struct. Biol. 4 1997 311 316
44. C.B. Breitenlechner, M. Gaßel, H. Hidaka, V. Kinzel, R. Huber, R.A. Engh, and D. Bossemeyer Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil (HA-1077) and H-1152P: structural basis of selectivity Structure 11 2003 1595 1607
45. W.M. Rockey, and A.H. Elcock Rapid computational identification of the targets of protein kinase inhibitors J. Med. Chem. 48 2005 4138 4152
46. M.L. Pusey, Z.-J. Liu, W. Tempel, J. Praissman, D. Linb, B.-C. Wang, J.A. Gavirac, and J.D. Ng Life in the fast lane for protein crystallization and X-ray crystallography Prog. Biophys. Mol. Biol. 88 2005 359 386
47. T.L. Blundell, H. Jhoti, and C. Abell High-throughput crystallography for lead discovery in drug design Nat. Rev., Drug Discov. 1 2002 45 54
48. B. Rupp, B.W. Segelke, I. Krupka, T. Lekin, J. Schäfer, A. Zemla, D. Toppani, G. Snell, and T. Earnest The TB structural genomics consortium crystallization facility: towards automation from protein to electron density Acta Cryst. D58 2002 1514 1518
49. S. DiMarco, and J.P. Priestle Structure of the complex of leech-derived tryptase inhibitor (LDTI) with trypsin and modeling of the LDTI-tryptase system Structure 5 1997 1465 1474
50. C.B. Breitenlechner, Röntgenkristallographische Untersuchungen von Inhibitor-Komplexen der Proteinkinase A und der Kinasedomäne von Src, Ph.D. Thesis, TU München, 2004.
51. C.B. Breitenlechner, R.A. Engh, R. Huber, V. Kinzel, D. Bossemeyer, and M. Gaßel The typically disordered N-terminus of PKA can fold as a helix and project the myristoylation site into solution Biochemistry 43 2004 7743 7749
52. R.A. Engh, A. Girod, V. Kinzel, R. Huber, and D. Bossemeyer Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolinesulfonyl protein kinase inhibitors H7, H8, and H89. Structural implications for selectivity J. Biol. Chem. 271 1996 26157 26164
53. W. Wen, and S.S. Taylor High affinity binding of the heat-stable protein kinase inhibitor to the catalytic subunit of cAMP-dependent protein kinase is selectively abolished by mutation of Arg133 J. Biol. Chem. 269 1994 8423 8430
54. M. Gaßel, C.B. Breitenlechner, N. König, R. Huber, R.A. Engh, and D. Bossemeyer The protein kinase C inhibitor bisindolyl-maleimide II binds with reversed orientations to different conformations of PKA J. Biol. Chem. 279 2004 23679 23690
55. M. Wisniewska, Biochemical Studies on IGF and IGF-Binding Proteins Interactions and Structural Investigations on the SH3 Domain of Crk-associated Tyrosine Kinase Substrate p130cas (CAS) Ph.D thesis, TU München, 2005.
56. T. Rehm, R. Huber, and T.A. Holak Application of NMR in structural proteomics: screening for proteins amenable to structural analysis Structure 10 2002 1613 1618
57. M.H.J. Seifert, C.B. Breitenlechner, D. Bossemeyer, R. Huber, T.A. Holak, and R.A. Engh Phosphorylation and flexibility of cyclic-AMP dependent protein kinase (PKA) using P-31 NMR spectroscopy Biochemistry 41 2002 5968 5977
58. R. Kiefersauer, H. Dobbek, M.E. Than, and R. Huber A novel free-mounting system for protein crystals: improvement of diffraction power by accurately controlled humidity changes Acta Cryst. A58 2002 C150
59. D. Rauh, G. Klebe, J. Stürzebecher, and M.T. Stubbs ZZ made EZ: influence of inhibitor configuration on enzyme selectivity J. Mol. Biol. 330 2003 761 770
60. J. Bain, H. McLauchlan, M. Elliott, and P. Cohen The specificities of protein kinase inhibitors: an update Biochem. J. 371 2003 199 204
61. C.B. Breitenlechner, T. Wegge, L. Berillon, K. Graul, K. Marzenell, W. Friebe, U. Thomas, R. Schumacher, R. Huber, R.A. Engh, and B. Masjost Structure-based optimization of novel azepane derivatives as PKB inhibitors J. Med. Chem. 47 2004 1375 1390
62. P. Kulanthaivel, Y. Hallock, C. Boros, S.M. Hamilton, W.P. Janzen, L.M. Ballas, C.R. Loomis, J.B. Jiang, J.B. Katz, J.R. Steiner, and J. Clardy Balanol: a novel and potent inhibitor of protein kinase C from the Fungus Verticillium balanoides J. Am. Chem. Soc. 115 1993 6452 6453
63. S. Ohshima, M. Yanagisawa, A. Katoh, T. Fujii, T. Sano, S. Matsukuma, T. Furumai, M. Fujiu, K. Watanabe, and K. Yokose Fusarium merismoides Corda NR 6356, the source of the protein kinase C inhibitor, azepinostatin. Taxonomy, yield improvement, fermentation and biological activity J. Antibiot. (Tokyo) 47 1994 639 647
64. T. Matsui, M. Amano, T. Yamamoto, K. Chihara, M. Nakafuku, M. Ito, T. Nakano, K. Okawa, A. Iwamatsu, and K. Kaibuchi Rho-associated kinase, a novel serine threonine kinase, as a putative target for the small GTP binding protein Rho EMBO J. 15 1996 2208 2216
65. M. Gaßel, C. Breitenlechner, P. Rüger, U. Jucknischke, T. Schneider, V. Kinzel, R. Huber, D. Bossemeyer, and R.A. Engh Mutants of protein kinase A that mimic the ATP-binding site of protein kinase B (AKT) J. Mol. Biol. 329 2003 1021 1034
66. C.B. Breitenlechner, W.-G. Friebe, E. Brunet, G. Werner, K. Graul, U. Thomas, K.-P. Künkele, W. Schäfer, M. Gassel, D. Bossemeyer, R. Huber, R.A. Engh, and B. Masjost Design and crystal structures of protein kinase B selective inhibitors in complex with protein kinase A and mutants J. Med. Chem. 48 2005 163 170
67. N. Narayana, T.C. Diller, K. Koide, M.E. Bunnage, K.C. Nicolaou, L.L. Brunton, N.H. Xuong, L.F. Ten Eyck, and S.S. Taylor Crystal structure of the potent natural product inhibitor balanol in complex with the catalytic subunit of cAMP-dependent protein kinase Biochemistry 38 1999 2367 2376
68. P.H. Hunenberger, V. Helms, N. Narayana, S.S. Taylor, and J.A. McCammon Determinants of ligand binding to cAMP dependent protein kinase Biochemistry 38 1999 2358 2366